News

Theriva™ Biologics Set to Showcase Innovations in Oncology

Theriva™ Biologics Set to Showcase Innovations in Oncology

Theriva™ Biologics to Present at the NeauxCancer Conference

Theriva™ Biologics (NYSE American: TOVX), a pioneering clinical-stage enterprise based in Rockville, is on the forefront of developing innovative therapeutics aimed at addressing cancer and related diseases, particularly in areas where there is a significant unmet medical need. The company’s management has announced an important upcoming engagement at the NeauxCancer 2025 Conference, scheduled to occur from March 27th to 29th.

Event Highlights and Company Presentation

During this conference, taking place at The Roosevelt New Orleans Hotel, Theriva™ will be featured in the Innovation track, specifically on March 28th at 9:00 AM. This track is dedicated to showcasing emerging biotech and healthcare companies that are making headway in cancer detection and treatment technologies. The opportunity for Theriva™ to present its cutting-edge research is a testament to the importance of its contributions to oncology.

Networking and One-on-One Meetings

Theriva’s management team will make themselves available for one-on-one meetings throughout the duration of the conference. This invites interested investors and stakeholders to engage directly with the leadership of Theriva™, facilitating discussions that could propel the future of cancer therapies. Those interested in scheduling a meeting are encouraged to reach out to the provided investor relations representative.

Advancing Cancer Treatment Technologies

Theriva™ Biologics specializes in crafting specialized therapeutics that aim to enhance the way cancer is treated. A key component of their strategy is the development of a novel oncolytic adenovirus platform designed for diverse delivery methods, including intravenous (IV) and intravitreal applications. The objective is clear: to stimulate tumor cell death while enhancing the delivery of existing cancer therapies to tumors, ultimately promoting a strong immune response against cancers.

The Company’s Pioneering Candidates

Among the standout candidates in Theriva's pipeline are:

  • VCN-01: This is an oncolytic adenovirus tailored to replicate specifically within tumor cells, reducing resistance that often complicates cancer treatment.
  • SYN-004 (ribaxamase): Crafted to mitigate the detrimental effects of commonly used IV beta-lactam antibiotics on the gut microbiome, it strives to prevent issues like the overgrowth of harmful pathogens and the severity of acute graft-versus-host disease (aGVHD) in patients undergoing hematopoietic cell transplants.
  • SYN-020: Offered as a recombinant oral formulation of intestinal alkaline phosphatase (IAP), it aims to treat various local gastrointestinal and systemic diseases.

These innovative approaches place Theriva™ Biologics as a leading entity in the quest for viable cancer therapies.

Contact and Further Information

For more details regarding Theriva™ Biologics and its cutting-edge projects, stakeholders can tap into their official website. Individuals interested in reaching out for additional information or inquiries can contact Kevin Gardner from LifeSci Advisors. More specific details are shared as follows:

Contact Details

Investor Relations:
Kevin Gardner
LifeSci Advisors, LLC
Email: kgardner@lifesciadvisors.com
Phone: 617-283-2856

Frequently Asked Questions

What is Theriva™ Biologics focusing on?

Theriva™ Biologics is dedicated to developing therapeutics designed to combat cancer and other related diseases.

When is the NeauxCancer 2025 Conference?

The conference will take place from March 27th to March 29th, 2025.

Where can I learn more about Theriva™ Biologics?

For more information, visit the official website of Theriva™ Biologics.

How can I schedule a meeting with Theriva™ during the conference?

Interested individuals should contact Theriva’s investor relations representative for meeting arrangements.

What innovative products does Theriva™ have in development?

Theriva™'s pipeline includes VCN-01, SYN-004, and SYN-020, each targeting specific challenges in cancer treatment.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 99

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
Paris vs. Berlin: Europe's Urban Driving Chaos Revealed

Updated Category News Views 103

Paris in the Fast Lane to Danger Paris, the city of love, is also the city of reckless acceleration if you peek at Geotab’s data. The City of Light isn’t just known for its romance and baguettes anymore; it’s got quite a knack for harsh driving events—1,191 per 1,000 trips, to be precise. That's a mind-boggling 5.3 times more than Berlin, the sensible sibling. A...

Continue Reading
Blue Angels Super Hornet Makes Historic Retirement

Updated Category News Views 16

The Palm Springs Air Museum is set to host a retirement party that could only be described as larger than life, and not because they've got a cake big enough for a 30th birthday bash. Nope, the real star is a jet—specifically, the Blue Angels F/A-18 Super Hornet that got its share of screen time in Top Gun: Maverick. First Public Retreat for a Super Hornet Saturday,...

Continue Reading
Upright Proton Therapy: New Era for Cancer Care

Updated Category News Views 0

BayCare's Bold Step into Upright Proton Therapy Here's a twist for you—BayCare Health System has rolled out something that's genuinely pushing the envelope in cancer treatment. They've treated their first patient with an upright proton therapy system. Now, talk about innovation that shakes things up. This isn't just any old upgrade; it's a complete revamp of how proton...

Continue Reading
Veteran-Friendly U.S. Cities in 2026: Who's Leading?

Updated Category News Views 76

Veterans Find Their Business Groove in U.S. Cities Around the diner's counter, traders might be swapping tales of market victories or lamenting lost opportunities. But today, we're chewing over a different kind of success story—the top U.S. cities paving the way for veteran entrepreneurs, courtesy of a fresh report from the PenFed Foundation for Military Heroes. This...

Continue Reading
Willig, Williams & Davidson Snags 2027 Best Law Firm Ranks

Updated Category News Views 19

A Legal Behemoth With A Winning Streak Stirring the pot in the legal world once again, Willig, Williams & Davidson stands tall, garnering praise in the 2027 'Best Law Firms'. This outfit isn't just another suit in the game. With roots deep in labor, employment, and family law, they went ahead and snagged prestigious national and metro-level rankings. Now, I've chewed...

Continue Reading
LV Petroleum Hits Major Expansion Milestone Nationwide

Updated Category News Views 55

LV Petroleum Revvs Up with Nationwide Growth This ain't your granddad's pit stop anymore. With LV Petroleum hitting the big 100 mark in travel centers, we're not just talking fuel and snacks here. Over the past 14 months, they bulked up from 42 sites to this triple-digit milestone. That's putting the pedal to the metal, no doubt. What's in it for Drivers and Communities...

Continue Reading
Admetec Shines Bright with New High-Magnification Headlights

Updated Category News Views 80

Admetec's Leap into Advanced Optical Solutions In the world of optical magnification, getting the right balance of visibility and comfort hasn't always been a straightforward journey. Now, Admetec, coming out of Haifa, Israel, is throwing a game-changer into the mix with their announcement of the Butterfly EVO+ and Orchid+ series. These ain't just any old headlights;...

Continue Reading
Grand Canyon Education's Q3 2026: Financial Gains and Insights

Updated Category News Views 89

Grand Canyon Education Post Strong Q3 2026 Results Picture this: a company like Grand Canyon Education, Inc. (NASDAQ: LOPE), after years in the education services game, dropping its Q3 2026 financial results with a blend of steady growth and strategic tweaks. Not bad for a Tuesday morning in the world of public education services, eh? Revenue Growth and Enrollment Gains...

Continue Reading
NNB Nutrition Unveils Revolutionary Ingredient Advances

Updated Category News Views 136

Sweet Innovation in a Natural Package Gotta hand it to NNB Nutrition—they’re not just shaking things up; they’re blending it into a whole new flavor universe. At the SupplySide Global 2026 in Vegas, NNB threw down some hefty advancements that might make even ol' Rockefeller sit up and take notice. We're talking about SweetVantage®, their brand-new creation that's...

Continue Reading

Top 5 Most Recently Viewed Articles

Beneficient's Transformative Fiscal Year: Key Financial Insights

Updated Category News Views 201

Beneficient's Transformative Year: Overview of Fiscal 2025 Beneficient (NASDAQ: BENF), a pioneering technology-enabled platform focused on revolutionizing the alternative asset investment landscape, has shared significant developments from its fiscal year ended March 31, 2025. The company has made strides in operational efficiencies, reduced costs, and launched innovative...

Continue Reading
Education as a Catalyst for Ending Leprosy Stigma Worldwide

Updated Category News Views 91

Empowering Through Education: A Global Appeal The call to action from the Global Appeal to End Stigma and Discrimination Against Persons Affected by Leprosy underscores a significant truth: education is a powerful tool that can change lives. Recently launched in Brussels, this initiative celebrated its 21st year with renewed vigor, emphasizing the critical role education...

Continue Reading
Investigation Launched into Albany International Corporation on Behalf of Investors

Updated Category News Views 138

Investigation into Albany International Corporation Albany International Corporation has become the subject of an investigation led by the law firm Kirby McInerney LLP. The firm aims to represent the interests of investors who may have been affected by potential violations of federal securities laws by the company or its officers. Details Regarding the Investigation This...

Continue Reading
Banijay Group Reports Its Weekly Share Transactions

Updated Category News Views 163

Weekly Share Transactions of Banijay Group Banijay Group N.V. recently disclosed its share transactions, which are vital for investors and stakeholders eager to understand the company's performance and shareholder engagements. In compliance with the authority granted during the previous shareholders' annual meeting, these transactions were conducted from early June,...

Continue Reading
Iridex's Innovative Study on MicroPulse Treatment for DME

Updated Category News Views 127

Revolutionizing Diabetic Macular Edema Treatment MOUNTAIN VIEW, Calif. – Iridex Corporation (Nasdaq: IRIX), a leader in laser-based medical systems, has taken a remarkable step forward in the treatment of diabetic macular edema (DME). The company recently announced the successful enrollment of the first patient in the DAME Trial. This pivotal study aims to assess the...

Continue Reading